Gilead Sciences Estonia EFPIA Report 2024  Date of publication: 01/06/2025														
						Donations and Grants	Contribution to costs of Events			Fee for service and consultancy		Date of publicat	ation: 01/06/2025	
	Full name	HCPs: City of Principal Practice HCOs: city where registered	Country of Principal Practice	Principal Practice Address	Unique country identifier OPTIONAL		Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an Event		Travel & Accommodation	Fees	Related expenses agreed in the fee for service or consultancy contract, including travel & accommodation relevant to the contract	Total	Total (optional)	
		INDIVIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)												
HCP-s						N/A	N/A							
		OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons												
	Aggregate amount attributable to transfers of value to such Recipients					N/A	N/A		5,974.61€				5,974.61 €	
	Number of Recipients in aggregate disclosure					N/A	N/A		8				8	
	% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed						N/A		100%				N/A	
	INDIVIDUAL NAMED DISCLOSURE - one line per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)													
													1	
HCO-s	OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons													
오	Aggregate amount attributable to transfers of value to such Recipients													
	Number of Recipients in aggregate disclosure													
	% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed													
	AGGREGATE DISCLOSURE													
R&D														
	Transfers of Value re Research & Development as defined												5,974.61€	